Related Experiment Video

Updated: Jun 17, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Sleep duration and hyperglycemia among obese and nonobese children aged 3 to 6 years

Zhen Tian1, Tao Ye, Xiaoyan Zhang

  • 1Tianjin Women and Children's Health Center, Tianjin, China.

Archives of Pediatrics & Adolescent Medicine
|January 6, 2010
PubMed

Insights

Shorter sleep duration is linked to a higher risk of hyperglycemia in young Chinese children. This association persists even after accounting for obesity and other factors, highlighting sleep

Area of Science:

  • Pediatric Endocrinology
  • Sleep Medicine
  • Public Health

Background:

  • Childhood obesity is a growing concern with potential metabolic consequences.
  • Hyperglycemia in children can indicate underlying metabolic dysfunction.
  • Understanding modifiable risk factors for hyperglycemia is crucial for early intervention.

Purpose of the Study:

  • To examine the relationship between sleep duration and hyperglycemia risk in preschool-aged Chinese children.
  • To determine if sleep duration is an independent risk factor for hyperglycemia in this population.

Main Methods:

  • A population-based cross-sectional study involving 71 kindergartens in Tianjin, China.
  • Recruitment of 619 obese and 617 nonobese children aged 3-6 years, matched by age.
  • Assessment of sleep duration and measurement of fasting glucose levels to define hyperglycemia (≥100 mg/dL).

Main Results:

  • Obese children exhibited significantly shorter sleep durations (< or =8 hours) compared to nonobese children.
  • Children sleeping 8 hours or less had a 1.65-fold increased likelihood of hyperglycemia compared to those sleeping 9-10 hours (OR, 1.65; 95% CI, 1.12-2.45), even after adjustments.
  • The association remained significant in stratified analyses, with obese children sleeping <=8 hours showing a 2.12-fold increased risk (OR, 2.12; 95% CI, 1.06-4.21).

Conclusions:

  • Shorter sleep duration is significantly associated with an elevated risk of hyperglycemia in preschool Chinese children.
  • The findings suggest that inadequate sleep may contribute to metabolic dysregulation in this age group.
  • Further research is needed to explore the role of adequate sleep in maintaining normal glucose levels, particularly in overweight and obese children.
Abstract

More Related Videos

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults06:13

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

Related Concept Videos

Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...